Avanos Medical Financial Statements (AVNS)
|
|
|
|
Report date
|
|
|
31.12.2022 |
21.02.2023 |
21.02.2024 |
26.02.2025 |
24.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
820.0 |
684.1 |
673.3 |
687.8 |
701.2 |
|
715.9 |
|
Operating Income, bln rub |
|
|
74.0 |
41.9 |
65.0 |
40.0 |
-61.6 |
|
-60.0 |
|
EBITDA, bln rub |
? |
|
122.9 |
77.8 |
50.6 |
-345.6 |
-33.2 |
|
-29.6 |
|
Net profit, bln rub |
? |
|
50.5 |
50.5 |
-61.8 |
-392.1 |
-67.9 |
|
-69.4 |
|
|
OCF, bln rub |
? |
|
90.9 |
90.9 |
32.4 |
100.7 |
74.7 |
|
49.0 |
|
CAPEX, bln rub |
? |
|
19.3 |
19.3 |
17.8 |
17.8 |
31.6 |
|
24.9 |
|
FCF, bln rub |
? |
|
71.6 |
71.6 |
14.6 |
82.9 |
43.1 |
|
24.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
376.0 |
352.3 |
314.7 |
341.3 |
410.6 |
|
333.3 |
|
Cost of production, bln rub |
|
|
370.0 |
289.9 |
293.6 |
306.5 |
352.2 |
|
362.5 |
|
R&D, bln rub |
|
|
30.6 |
30.6 |
27.2 |
26.2 |
23.1 |
|
22.9 |
|
Interest expenses, bln rub |
|
|
10.00 |
10.00 |
15.0 |
12.2 |
4.00 |
|
7.20 |
|
|
Assets, bln rub |
|
|
1 787 |
1 787 |
1 692 |
1 154 |
1 074 |
|
1 050 |
|
Net Assets, bln rub |
? |
|
1 291 |
1 291 |
1 236 |
828.5 |
778.2 |
|
782.1 |
|
Debt, bln rub |
|
|
280.0 |
277.0 |
209.1 |
170.2 |
129.1 |
|
138.4 |
|
Cash, bln rub |
|
|
127.7 |
127.7 |
87.7 |
107.7 |
89.8 |
|
65.6 |
|
Net debt, bln rub |
|
|
152.3 |
149.3 |
121.4 |
62.5 |
39.3 |
|
72.8 |
|
|
Ordinary share price, rub |
|
|
27.1 |
27.1 |
22.4 |
15.9 |
11.2 |
|
21.5 |
|
Number of ordinary shares, mln |
|
|
46.9 |
46.9 |
46.6 |
46.0 |
46.4 |
|
46.4 |
|
|
Market cap, bln rub |
|
|
1 269 |
1 269 |
1 045 |
732 |
521 |
|
999 |
|
EV, bln rub |
? |
|
1 421 |
1 418 |
1 167 |
795 |
560 |
|
1 072 |
|
Book value, bln rub |
|
|
221 |
297 |
201 |
261 |
266 |
|
273 |
|
|
EPS, rub |
? |
|
1.08 |
1.08 |
-1.33 |
-8.52 |
-1.46 |
|
-1.50 |
|
FCF/share, rub |
|
|
1.53 |
1.53 |
0.31 |
1.80 |
0.93 |
|
0.52 |
|
BV/share, rub |
|
|
4.71 |
6.33 |
4.31 |
5.67 |
5.72 |
|
5.89 |
|
|
EBITDA margin, % |
? |
|
15.0% |
11.4% |
7.52% |
-50.2% |
-4.73% |
|
-4.13% |
|
Net margin, % |
? |
|
6.16% |
7.38% |
-9.18% |
-57.0% |
-9.68% |
|
-9.69% |
|
FCF yield, % |
? |
|
5.64% |
5.64% |
1.40% |
11.3% |
8.27% |
|
2.41% |
|
ROE, % |
? |
|
3.91% |
3.91% |
-5.00% |
-47.3% |
-8.73% |
|
-8.87% |
|
ROA, % |
? |
|
2.83% |
2.83% |
-3.65% |
-34.0% |
-6.32% |
|
-6.61% |
|
|
P/E |
? |
|
25.1 |
25.1 |
-16.9 |
-1.87 |
-7.67 |
|
-14.4 |
|
P/FCF |
|
|
17.7 |
17.7 |
71.6 |
8.83 |
12.1 |
|
41.5 |
|
P/S |
? |
|
1.55 |
1.86 |
1.55 |
1.06 |
0.74 |
|
1.40 |
|
P/BV |
? |
|
5.75 |
4.28 |
5.21 |
2.81 |
1.96 |
|
3.66 |
|
EV/EBITDA |
? |
|
11.6 |
18.2 |
23.1 |
-2.30 |
-16.9 |
|
-36.2 |
|
Debt/EBITDA |
|
|
1.24 |
1.92 |
2.40 |
-0.18 |
-1.18 |
|
-2.46 |
|
|
R&D/CAPEX, % |
|
|
158.5% |
158.5% |
152.8% |
147.2% |
73.1% |
|
92.0% |
|
|
CAPEX/Revenue, % |
|
|
2.35% |
2.82% |
2.64% |
2.59% |
4.51% |
|
3.48% |
|
| Avanos Medical shareholders |
